A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT

Bone Marrow Transplantation

Volumn 46, Issue 11, 2011, Pages 1455-1463

  Espinoza, J L ^a   Takami, A ^a   Onizuka, M ^b   Kawase, T ^c   Sao, H ^d   Akiyama, H ^e   Miyamura, K ^f   Okamoto, S ^g   Inoue, M ^h   Ohtake, S ^a   Fukuda, T ⁱ   Morishima, Y ^c   Kodera, Y ^j   Nakao, S ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d Meitetsu Hospital   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^g KEIO UNIVERSITY   (Japan)

^h RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL   (Japan)

^j AICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

IL 17; single nucleotidepolymorphis; unrelated donor

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INTERLEUKIN 17 GENE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; GRAFT VS HOST DISEASE; HUMANS; INFANT; INTERLEUKIN-17; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

EID: 80855134362     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.325     Document Type: Article

References (59)

1. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: An EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-769. (Pubitemid 41613298)
2. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 2004; 127: 479-490. (Pubitemid 39627172)
3. Elmaagacli AH, Koldehoff M, Landt O, Beelen DW. Relation of an interleukin-23 receptor gene polymorphism to graftversus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant 2008; 41: 821-826. (Pubitemid 351696347)
4. Gerbitz A, Hillemanns P, Schmid C, Wilke A, Jayaraman R, Kolb HJ et al. Influence of polymorphism within the heme oxygenase-I promoter on overall survival and transplantationrelated mortality after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 1180-1189.
5. Kim DH, Jung HD, Lee NY, Sohn SK. Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. Transplantation 2007; 84: 917-925. (Pubitemid 351338954)
6. Noori-Daloii MR, Rashidi-Nezhad A, Izadi P, Hossein-Nezhad A, Sobhani M, Derakhshandeh-Peykar P et al. Transforming growth factor-beta1 codon 10 polymorphism is associated with acute GVHD after allogenic BMT in Iranian population. Ann Transplant 2007; 12: 5-10.
7. Viel DO, Tsuneto LT, Sossai CR, Lieber SR, Marques SB, Vigorito AC et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand J Immunol 2007; 66: 703-710. (Pubitemid 350132635)
8. Sugimoto K, Murata M, Onizuka M, Inamoto Y, Terakura S, Kuwatsuka Y et al. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int J Hematol 2008; 87: 451-458.
9. Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A. Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: Effect of discrepancy between recipients and donors. Blood 2010; 115: 2319-2328.
10. Takami A, Espinoza JL, Onizuka M, Ishiyama K, Kawase T, Kanda Y et al. A single-nucleotide polymorphism of the Fcgamma receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. Bone Marrow Transplant 2010 (e-pub ahead of print 19 April 2010; doi:10.1038/bmt.2010.88)
11. McDermott DH, Conway SE, Wang T, Ricklefs SM, Agovi MA, Porcella SF et al. Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. Blood 2010; 115: 2311-2318.
12. Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K et al. NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica 2009; 94: 1427-1434.
13. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3: 811-821. (Pubitemid 26091152)
14. Yu JJ, Gaffen SL. Interleukin-17: A novel inflammatory cytokine that bridges innate and adaptive immunity. Front Biosci 2008; 13: 170-177. (Pubitemid 351594768)
15. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-567.
16. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-898.
17. O'Brien RL, Roark CL, Born WK. IL-17-producing gammadelta T cells. Eur J Immunol 2009; 39: 662-666.
18. Schulz SM, Kohler G, Holscher C, Iwakura Y, Alber G. IL-17A is produced by Th17, gammadelta T cells and other CD4-lymphocytes during infection with Salmonella enterica serovar Enteritidis and has a mild effect in bacterial clearance. Int Immunol 2008; 20: 1129-1138.
19. Awasthi A, Kuchroo VK. Th17 cells: From precursors to players in inflammation and infection. Int Immunol 2009; 21: 489-498.
20. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009; 30: 108-119.
21. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161: 409-414. (Pubitemid 28285549)
22. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54: 1122-1131. (Pubitemid 43672925)
23. Ciprandi G, De Amici M, Murdaca G, Fenoglio D, Ricciardolo F, Marseglia G et al. Serum interleukin-17 levels are related to clinical severity in allergic rhinitis. Allergy 2009; 64: 1375-1378.
24. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70. (Pubitemid 36020767)
25. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide comparison between IL-17A-and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol 2009; 182: 3112-3120.
26. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999; 162: 577-584. (Pubitemid 29018969)
27. Vanaudenaerde BM, Dupont LJ, Wuyts WA, Verbeken EK, Meyts I, Bullens DM et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006; 27: 779-787. (Pubitemid 44914203)
28. Van Kooten C, Boonstra JG, Paape ME, Fossiez F, Banchereau J, Lebecque S et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998; 9: 1526-1534. (Pubitemid 28354565)
29. Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197: 322-332. (Pubitemid 34778302)
30. Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009; 114: 3101-3112.
31. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008; 112: 2101-2110.
32. Tawara I, Maeda Y, Sun Y, Lowler KP, Liu C, Toubai T et al. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Exp Hematol 2008; 36: 988-996.
33. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C et al. IL-17 contributes to CD4-mediated graft-versushost disease. Blood 2009; 113: 945-952.
34. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C et al. Th17 cells are sufficient but not necessary to induce acute graftversus-host disease. Biol Blood Marrow Transplant 2009; 16: 170-178.
35. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113: 1365-1374.
36. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol 2008; 28: 44-49.
37. Furuya T, Hakoda M, Ichikawa N, Higami K, Nanke Y, Yago T et al. Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis. Clin Rheumatol 2007; 26: 2137-2141. (Pubitemid 350120354)
38. Nordang GB, Viken MK, Hollis-Moffatt JE, Merriman TR, Forre OT, Helgetveit K et al. Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. Rheumatology (Oxford) 2009; 48: 367-370.
39. Southam L, Heath O, Chapman K, Loughlin J. Association analysis of the interleukin 17 genes IL17A and IL17F as potential osteoarthritis susceptibility loci. Ann Rheum Dis 2006; 65: 556-557.
40. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007; 110: 2235-2241. (Pubitemid 47523140)
41. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177-1185. (Pubitemid 28482126)
42. Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007; 13: 315-328.
43. Livak KJ. Allelic discrimination using fluorogenic probes and the 50 nuclease assay. Genet Anal 1999; 14: 143-149. (Pubitemid 29095371)
44. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
45. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217. (Pubitemid 10036817)
46. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: An easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387. (Pubitemid 47202424)
47. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
48. Shibata T, Tahara T, Hirata I, Arisawa T. Genetic polymorphism of interleukin-17A and-17F genes in gastric carcinogenesis. Hum Immunol 2009; 70: 547-551.
49. Alexandra HF, Daniel W, Steven P, Gerard S, John RW, Stephanie JL et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I.Diagnosis and Staging Working Group Report. Biol Blood and Marrow Transplantation 2005; 11: 945-956.
50. Murashige N, Kami M, Mori S, Katayama Y, Kobayashi K, Onishi Y et al. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor. Am J Hematol 2008; 83: 630-634.
51. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem H-P et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114: 702-708.
52. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415. (Pubitemid 29343964)
53. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575-581. (Pubitemid 34633434)
54. Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004; 172: 7393-7398. (Pubitemid 38747600)
55. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALLTrial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833. (Pubitemid 351451489)
56. Thomas E, Buckner C, Banaji M, Clift R, Fefer A, Flournoy N et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511-533. (Pubitemid 8080182)
57. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008. (Pubitemid 38326213)
58. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 2001; 98: 2043-2051.
59. Miller RA. The aging immune system: Primer and prospectus. Science 1996; 273: 70-74. (Pubitemid 26255423)